Protein stability effects in aggregate-based enzyme inhibition.
暂无分享,去创建一个
[1] B. Shoichet,et al. A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.
[2] B K Shoichet,et al. A relationship between protein stability and protein function. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[3] B. Shoichet,et al. A New Spin on Antibody-Drug Conjugates: Trastuzumab-Fulvestrant Colloidal Drug Aggregates Target HER2-Positive Cells. , 2017, ACS applied materials & interfaces.
[4] B. Shoichet,et al. Colloidal Drug Aggregate Stability in High Serum Conditions and Pharmacokinetic Consequence. , 2019, ACS chemical biology.
[5] B. Shoichet,et al. Functional analyses of AmpC β‐lactamase through differential stability , 1999 .
[6] B. Shoichet,et al. Identification and prediction of promiscuous aggregating inhibitors among known drugs. , 2003, Journal of medicinal chemistry.
[7] T. Kunkel. Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[8] Rajeevan Selvaratnam,et al. Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators. , 2019, Journal of medicinal chemistry.
[9] B. Shoichet,et al. Interaction energies between β‐lactam antibiotics and E. coli penicillin‐binding protein 5 by reversible thermal denaturation , 2001, Protein science : a publication of the Protein Society.
[10] B. Shoichet,et al. Colloidal Aggregation Affects the Efficacy of Anticancer Drugs in Cell Culture , 2012, ACS chemical biology.
[11] John D. Chodera,et al. Quantitative Self-Assembly Prediction Yields Targeted Nanomedicines , 2017, Nature Materials.
[12] Functional analyses of AmpC beta-lactamase through differential stability. , 1999, Protein science : a publication of the Protein Society.
[13] Brian K Shoichet,et al. Colloidal aggregation: from screening nuisance to formulation nuance. , 2018, Nano today.
[14] B. Shoichet,et al. Noncovalent interaction energies in covalent complexes: TEM‐1 β‐lactamase and β‐lactams , 2002 .
[15] D. Elnatan,et al. Internal Structure and Preferential Protein Binding of Colloidal Aggregates. , 2017, ACS chemical biology.
[16] B. Shoichet,et al. Noncovalent interaction energies in covalent complexes: TEM-1 beta-lactamase and beta-lactams. , 2002, Proteins.
[17] D. G. Gibson,et al. Enzymatic assembly of DNA molecules up to several hundred kilobases , 2009, Nature Methods.
[18] B. Shoichet,et al. High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.
[19] B. Shoichet,et al. Stable Colloidal Drug Aggregates Catch and Release Active Enzymes. , 2016, ACS chemical biology.
[20] Brian K Shoichet,et al. A detergent-based assay for the detection of promiscuous inhibitors , 2006, Nature Protocols.
[21] Maria F. Sassano,et al. Colloidal Aggregation Causes Inhibition of G Protein-Coupled Receptors , 2013, Journal of medicinal chemistry.
[22] B. Shoichet,et al. Colloidal aggregation and the in vitro activity of traditional Chinese medicines. , 2015, ACS chemical biology.
[23] Paul J Lewi,et al. Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability. , 2005, Journal of medicinal chemistry.
[24] John G. Quinn,et al. Unlocking latent kinetic information from label-free binding , 2019, Scientific Reports.
[25] Lynne S Taylor,et al. Enhancements and limits in drug membrane transport using supersaturated solutions of poorly water soluble drugs. , 2014, Journal of pharmaceutical sciences.
[26] Anthony M Giannetti,et al. Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. , 2008, Journal of medicinal chemistry.
[27] Kristin E. D. Coan,et al. Promiscuous Aggregate-Based Inhibitors Promote Enzyme Unfolding , 2009, Journal of medicinal chemistry.
[28] Christopher P Austin,et al. Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. , 2010, Journal of medicinal chemistry.
[29] B. Shoichet,et al. Inhibition of AmpC beta-lactamase through a destabilizing interaction in the active site. , 2001, Biochemistry.
[30] B. Shoichet,et al. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.
[31] Brian K Shoichet,et al. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. , 2002, Journal of molecular biology.
[32] Laurent Maveyraud,et al. Structural Basis for Clinical Longevity of Carbapenem Antibiotics in the Face of Challenge by the Common Class A Beta-Lactamases from Antibiotic-Resistant Bacteria , 1998 .
[33] J. Irwin,et al. An Aggregation Advisor for Ligand Discovery. , 2015, Journal of medicinal chemistry.
[34] Kristin E. D. Coan,et al. Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. , 2008, Journal of the American Chemical Society.
[35] Christopher P Austin,et al. A high-throughput screen for aggregation-based inhibition in a large compound library. , 2007, Journal of medicinal chemistry.
[36] C. Partch,et al. Analysis of Protein Stability and Ligand Interactions by Thermal Shift Assay , 2015, Current protocols in protein science.
[37] Kenneth M Merz,et al. The Ecstasy and Agony of Assay Interference Compounds. , 2017, Journal of medicinal chemistry.